Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. Keeping that in mind, here are three profitable companies to avoid and some better opportunities instead.
AMC Networks (AMCX)
Trailing 12-Month GAAP Operating Margin: 4.4%
Originally the joint-venture of four cable television companies, AMC Networks (NASDAQ: AMCX) is a broadcaster producing a diverse range of television shows and movies.
Why Is AMCX Risky?
- Sales tumbled by 3.7% annually over the last five years, showing consumer trends are working against it
- Poor free cash flow margin of 11.2% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends
- Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
AMC Networks’s stock price of $9.61 implies a valuation ratio of 0.2x forward price-to-sales. To fully understand why you should be careful with AMCX, check out our full research report (it’s free).
Avery Dennison (AVY)
Trailing 12-Month GAAP Operating Margin: 11.8%
Founded as Kum Kleen Products, Avery Dennison (NYSE: AVY) is a manufacturer of adhesive materials, display graphics, and packaging products, serving various industries.
Why Is AVY Not Exciting?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- Projected sales growth of 3.9% for the next 12 months suggests sluggish demand
- Earnings growth over the last five years fell short of the peer group average as its EPS only increased by 4.3% annually
At $161.91 per share, Avery Dennison trades at 15.6x forward P/E. Check out our free in-depth research report to learn more about why AVY doesn’t pass our bar.
Regeneron (REGN)
Trailing 12-Month GAAP Operating Margin: 24.3%
Founded by scientists who wanted to build a company where science could thrive, Regeneron Pharmaceuticals (NASDAQ: REGN) develops and commercializes medicines for serious diseases, with key products treating eye conditions, allergic diseases, cancer, and other disorders.
Why Does REGN Worry Us?
- Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 6.7% for the last two years
- 20.4 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
- Eroding returns on capital suggest its historical profit centers are aging
Regeneron is trading at $611.85 per share, or 12.7x forward P/E. Read our free research report to see why you should think twice about including REGN in your portfolio.
Stocks We Like More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
